Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05541276

MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children

Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 1-6 years
  • Elective surgical procedure of en axpected duration of at least 30 minutes in general anesthesia maintained with sevoflurane

Exclusion criteria

  • Any known allergy or contraindication to study treatment or excipåients
  • Current daily medication with melatonin

Treatment and study plan

Melatonin

Drug

Melatonin for injection 1 mg/mL

Isotonic sodium chloride solution

Drug

Sodium chloride 0.9 % for injection

Other names: Normal saline

Primary outcomes

  1. Incidence of emergence agitation

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Participants will be assessed on Watcha scale repeatedly ever 15 min during their stay at the Post-Anesthetic Care Unit. The variable is dichotomous: any score >2= "Yes" and no score <=2 = "No"

Secondary outcomes

  1. Opioid consumption

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    The total amount of opioids administered for postoperative pain in the PACU will be evaluated as units of morphine equivalents per kg. No more than 35 % of the popu-lation is expected to receive postoperative opioids in a range of approximately 10-100 µg/kg.

  2. Non-serious Adverse Events (AE)

    Time frame: From enrolment to the trial until 24-hour follow-up.

    Any untoward medical occurrence not considered serious.

Other outcomes

  1. Serious Adverse Events (SAE)

    Time frame: SAEs will be assessed from enrolment until 30 days after intervention.

    We will use the International Conference on Harmonization of technical require-ments for registration of pharmaceuticals for human use-Good Clinical Practice (ICH-GCP) definition of a serious adverse event, which is any untoward medical occurrence that resulted in death, was life-threatening, re-quired hospitalization or prolonging of existing hospitalization and resulted in persistent or significant disability or jeopardized the participant.

  2. Postoperative pain

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    The incidence of postoperative pain will be assessed in each group according to the FLACC scale, assessed every 15 minutes in PACU. Postoperative pain is defined as any FLACC score >3.

  3. Postoperative nausea and vomiting (PONV)

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    The incidence of PONV will be assessed dichotomously every 15 minutes in PACU. Outcome assessors will observe for vomiting. Nausea can be considered present if the participant refuses to eat and other causes are ruled out. There is no adequate PONV assessment tool available. PONV will be considered present if any assess-ment during PACU stay is "Yes".

  4. Time to administration of opioid

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Time from end of anesthesia to the time point at which the first dose of opioid is administered in PACU. Not all participants (expectedly up to approximately 35%) will receive opioids in PACU.

  5. Need for rescue medication

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Dichotomous assessment of any administration in PACU of rescue medication specifically targeting EA according to treatment algorithm i.e., clonidine or propofol.

  6. Time to awakening in PACU

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Time from end of anesthesia to the first time point at which the participant is awake. If the participant is not awake two hours after arrival in PACU, a wake-up at-tempt will be carried out.

  7. Time to postoperative oral intake

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Time from end of anesthesia to the first time point at which the participant eats/drinks. All participants are assumed to eat/drink during their PACU stay.

  8. Time for discharge readiness

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    Time from end of anesthesia (defined as above) to the time point at which partici-pant fulfills local discharge criteria. Discharge criteria will be evaluated by the re-sponsible physician prior to final discharge from PACU either to the participant's ward or to their home.

  9. Emergence delirium

    Time frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).

    The incidence of emergence delirium will be evaluated according to the PAED score assessed every 15 minutes during PACU stay. The end-point is defined dichotomously as any score ≥10. Due to feasibility concerns, this outcome will solely be evaluated in a sub-population of approximately 50% of the trial population (200 participants), specifically only thos enrolled at the Juliane Marie Center Site.

  10. Readmissions within 30 days

    Time frame: From day of discharge + 30 days.

    Assessed dichotomously counting day 0 as the day of discharge from hospital after the procedure. For the small group (expectedly <5 %) who will have had any read-missions within 30 days, the number of readmissions will be described.

Study contacts

Contact information is provided by the study sponsor or research team.

Anne Louise B Garioud, MD

CONTACT

[email protected]

+4535456243

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Copenhagen Trial Unit, Center for Clinical Intervention Research
  • Sygehus Lillebaelt
  • University of Copenhagen

Registry information

Official study title

MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial.

Acronym: MELA-PAED

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 15, 2022
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.